Nevertheless, a recent analysis presented by Agrawal et al. demonstrated that prostate cancer–specific mortality and all-cause mortality calculated from the time of RP were indeed worse for patients treated with SRT at higher PSA levels (20) These findings corroborated those of Stish et al. (16). The gene discussed is KLK3; the disease is Familial prostate cancer.